Payment overview · 2025
General Payments
$493.77
25 reported records · 10 companies
Healthcare provider profile · identity verified
Swaranjit K Chani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HORSE CAVE, KY · NPI 1619953700
Verified facts
What the public records show
CMS Open Payments records show Swaranjit K Chani, M.D. received $493.77 in general payments during 2025 across 25 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.67 | 17.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.10 | 16.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $75.94 | 15.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $59.92 | 12.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.95 | 9.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.12 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.02 | 8.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.17 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.50 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.38 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $493.77 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.67 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $75.94 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $59.92 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.95 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 115 |
| Furosemide | Furosemide | 323 | 69 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 247 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 71 |
| Losartan Potassium | Losartan Potassium | 227 | 64 |
| Gabapentin | Gabapentin | 219 | 53 |
| Potassium Chloride | Potassium Chloride | 187 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 49 |
| Omeprazole | Omeprazole | 173 | 47 |
| Eliquis | Apixaban | 170 | 40 |
| Lisinopril | Lisinopril | 164 | 51 |
| Trazodone Hcl | Trazodone Hcl | 162 | 51 |
| Sertraline Hcl | Sertraline Hcl | 159 | 42 |
| Jardiance | Empagliflozin | 158 | 26 |
| Famotidine | Famotidine | 144 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 33 |
| Valsartan | Valsartan | 136 | 37 |
| Metformin Hcl | Metformin Hcl | 127 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 28 |
| Mirtazapine | Mirtazapine | 117 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 32 |
| Buspirone Hcl | Buspirone Hcl | 110 | 28 |
| Ozempic | Semaglutide | 101 | 26 |
| Carvedilol | Carvedilol | 98 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 35 |
| Divalproex Sodium | Divalproex Sodium | 95 | suppressed |
| Pregabalin | Pregabalin | 95 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 34 |
| Ezetimibe | Ezetimibe | 79 | 23 |
| Metformin Hcl Er | Metformin Hcl | 77 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 35 |
| Donepezil Hcl | Donepezil Hcl | 71 | 25 |
| Montelukast Sodium | Montelukast Sodium | 71 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Memantine Hcl | Memantine Hcl | 66 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 24 |
| Allopurinol | Allopurinol | 65 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 21 |
| Nystatin | Nystatin | 59 | 13 |
| Tramadol Hcl | Tramadol Hcl | 55 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 40 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Topiramate | Topiramate | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Baclofen | Baclofen | 42 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 13 |
| Meloxicam | Meloxicam | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 15 |
| Lactulose | Lactulose | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Prednisone | Prednisone | 36 | 24 |
| Bupropion Xl | Bupropion Hcl | 35 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 13 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 15 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 12 |
| Budesonide | Budesonide | 25 | suppressed |
| Nystop | Nystatin | 25 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 13 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 16 |
| Primidone | Primidone | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Klayesta | Nystatin | 17 | 11 |
| Atenolol | Atenolol | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nifedipine | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $493.77 · 25 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, FARXIGA, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error